Charles M. Lillis - 01 Sep 2021 Form 3 Insider Report for SomaLogic, Inc.

Role: Director
Signature: /s/ Ruben Gutierrez, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Sep 2021
Net transactions value: $0
Form type: 3
Filing time: 10 Sep 2021, 19:04:25 UTC
Next filing: 13 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLGC	Class A Common Stock, par value $0.0001						276,573	01 Sep 2021	Direct	F1
holding	SLGC	Class A Common Stock, par value $0.0001						100,572	01 Sep 2021	See Footnote	F1, F2
holding	SLGC	Class A Common Stock, par value $0.0001						12,571	01 Sep 2021	See Footnote	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SLGC	Employee Stock Option (Right to Buy)							01 Sep 2021	Class A Common Stock, par value $0.0001	20,952	$4.77	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock.
F2	Reflects stock held of record by The Lillis Foundation. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares.
F3	Reflects stock held of record by CAG LLC. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares.
F4	The shares underlying the option vest in 12 equal monthly installments starting on the 1st of the first full month following the date of the grant.
F5	In connection with the Closing, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards.